Genetic Pathways to Glioblastoma

By H. Ohgaki, Pierre Dessen, B. Jourde, Sonja Horstmann, Tomofumi Nishikawa, Pier-Luigi Di Patre, C. Burkhard, D. Schüler, N. Probst-Hensch, P. Maiorka and 6 more. Cancer Research, 2004

779 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/4acbe54cab2b2c3aeebf5a3ec4d41e11d00c8895

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. H. Ohgaki
2. P. Kleihues
3. Alec C. Kimmelman
4. R. DePinho

In Genetics

1. H. Ohgaki
2. P. Kleihues
3. Guido Reifenberger
4. Michael Weller
5. R. DePinho
6. R. Jenkins
7. McKinsey L. Goodenberger

In Oncology

1. N. Hynes
2. Alec C. Kimmelman
3. R. DePinho
4. J. Baselga

Citations in the corpus

• P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation (2008, positive): “These results, together with recent population-based studies 10, 11 , indicate that p53 is a key tumor suppressor for both GBM subtypes.”
• Genetic pathways to primary and secondary glioblastoma. (2007, background): “At a population level, primary glioblastomas developed more frequently in men (male to female ratio, 1:33), whereas secondary glioblastomas were more frequent in women (male to female ratio, 0:65).(5) A review of several studies also showed a tendency toward a higher male to female ratio in primary ”
• Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. (2009, background): “However, the clinical value of most glioma-associated molecular aberrations in terms of their significance as diagnostic, prognostic, or predictive molecular markers has remained unclear.(2-5) To date, only two molecular aberrations have been demonstrated to be of clinical significance in prospectiv”
• ERBB receptors and cancer: the complexity of targeted inhibitors (2005, background): “Gene amplification leading to EGFR overexpression is often found in human cancer”